Naltrexone: Effective Opioid and Alcohol Dependence Management
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $6.13 | $184.04 (0%) | 🛒 Add to cart |
| 60 | $5.81 | $368.08 $348.30 (5%) | 🛒 Add to cart |
| 90 | $5.69
Best per pill | $552.12 $511.70 (7%) | 🛒 Add to cart |
Synonyms | |||
Naltrexone is a competitive opioid antagonist medication indicated for the management of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It functions by binding to opioid receptors, thereby blocking the euphoric and sedative effects of opioids and reducing the craving for alcohol. Available in oral tablet and extended-release intramuscular formulations, naltrexone serves as a cornerstone in comprehensive addiction treatment protocols. Its efficacy is well-supported by clinical evidence when used as part of a broader therapeutic program that includes counseling and psychosocial support.
Features
- Pharmacological class: Opioid receptor antagonist
- Available formulations: 50 mg oral tablets; 380 mg extended-release intramuscular injection (Vivitrol®)
- Mechanism of action: Competitive binding at mu-opioid receptors
- Bioavailability: Oral: 5–40%; IM: sustained release over approximately 30 days
- Half-life: Oral: 4–13 hours; IM: 5–10 days (release phase)
- Metabolism: Primarily hepatic, via dihydrodiol dehydrogenase
- Excretion: Primarily renal
Benefits
- Reduces alcohol craving and decreases rates of relapse in alcohol-dependent patients
- Blocks the euphoric effects of opioids, supporting abstinence in opioid use disorder
- Non-addictive with no abuse potential, supporting long-term maintenance therapy
- Available in long-acting formulation to improve adherence and reduce dosing frequency
- Can be integrated into comprehensive treatment plans including behavioral therapy
- Helps restore neurochemical balance disrupted by chronic substance use
Common use
Naltrexone is primarily prescribed for two FDA-approved indications: treatment of alcohol use disorder and prevention of relapse in opioid use disorder. In alcohol dependence, it is used to reduce craving and the rewarding effects of alcohol consumption. For opioid dependence, it prevents the euphoric and reinforcing effects of exogenous opioids, thereby supporting abstinence. Off-label uses include treatment of other impulse control disorders, though evidence is less robust. It is typically initiated after a patient has undergone opioid detoxification and has been opioid-free for a minimum of 7–10 days to avoid precipitating withdrawal.
Dosage and direction
Oral formulation (tablets):
- Initial dose: 25 mg once daily, to assess tolerability
- Maintenance: 50 mg once daily
- May be taken with or without food to minimize gastrointestinal upset
Extended-release injectable (Vivitrol®):
- 380 mg administered intramuscularly every 4 weeks (or once monthly)
- Must be administered by a healthcare professional into the gluteal muscle
- Alternate buttocks for subsequent injections
Dosage adjustments are generally not required for renal or hepatic impairment, though caution is advised in severe hepatic disease. Treatment should be initiated under clinical supervision after confirming opioid-free status.
Precautions
- Patients must be opioid-free prior to initiation to avoid precipitated withdrawal
- Use with caution in patients with hepatic impairment; periodic LFT monitoring recommended
- Not recommended for acute pain management; alternative analgesia strategies are required
- May cause hepatocellular injury at excessive doses; adhere to prescribed dosing
- Injection-site reactions (including necrosis) may occur with intramuscular formulation
- Use in pregnancy only if potential benefit justifies potential risk to the fetus (Category C)
Contraindications
- Current physiologic opioid dependence or recent opioid use
- Acute opioid withdrawal syndrome
- Failure to pass a naloxone challenge test (if applicable)
- Acute hepatitis or liver failure
- Hypersensitivity to naltrexone or any component of the formulation
Possible side effect
Common (≥1%):
- Nausea (10%)
- Headache (7%)
- Dizziness (4–10%)
- Fatigue (4%)
- Insomnia (3–6%)
- Anxiety (2–5%)
- Injection site reactions (pain, induration, tenderness) with IM formulation
Less common:
- Abdominal pain/cramps
- Joint/muscle pain
- Rash
- Somnolence
- Increased thirst
Rare but serious:
- Hepatotoxicity (dose-related)
- Eosinophilic pneumonia (with injectable)
- Depression/suicidal ideation
- Severe injection site reactions including tissue necrosis
Drug interaction
- Opioid analgesics: diminished analgesic efficacy; may require higher doses (with caution)
- Opioid-containing medications (e.g., cough suppressants, antidiarrheals): reduced efficacy
- Thioridazine: reported lethargy and somnolence
- Disulfiram: increased risk of hepatotoxicity
- Clonidine: potential additive hypotensive effects (theoretical)
Missed dose
Oral tablets: Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double the dose.
Injectable formulation: Administer the next injection as soon as possible. Do not administer two injections simultaneously. Consult the prescribing physician for guidance on rescheduling.
Overdose
No specific antidote exists. Symptoms may include nausea, abdominal pain, dizziness, and hepatotoxicity at very high doses. Management is supportive and symptomatic. Hemodialysis is not effective due to high protein binding. In cases of suspected overdose, seek immediate medical attention. Note: Overdose on opioids while on naltrexone may require higher-than-usual naloxone doses and prolonged monitoring due to naltrexone’s prolonged receptor blockade.
Storage
- Store at controlled room temperature (20–25°C or 68–77°F)
- Protect from light and moisture
- Keep in original container
- Do not freeze the injectable suspension
- Keep out of reach of children and pets
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and individualized treatment recommendations. Do not initiate, adjust, or discontinue medication without professional supervision. The prescriber should be aware of the latest clinical guidelines and product labeling.
Reviews
Clinical consensus supports naltrexone as an effective adjunct in treating alcohol and opioid dependence, particularly when compliance is monitored. Patient responses vary; some report significant reduction in cravings, while others experience limited benefit. The monthly injection formulation is often preferred for adherence. Ongoing research continues to refine its role in addiction therapeutics.